X-twitter Linkedin Facebook-f Vimeo

Health

Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.

GENF

Genflow Biosciences to Attend BIO San Diego as Chairman Gad Berdugo Joins mRNA Panel

Genflow Biosciences will attend BIO San Diego, with chairman Gad Berdugo joining an mRNA panel...
GSK

GSK gains US FDA approval for oral cUTI antibiotic Utebzi

GSK has secured US FDA approval for Utebzi, an oral carbapenem antibiotic for certain adult patients with complicated urinary tract infections...
Cizzle Biotechnology

Cizzle Biotechnology US Launch Opens the Door to Lung Cancer Test Royalties (video)

Cizzle Biotechnology has reached a pivotal commercial milestone, with its CIZ1B lung cancer blood test now available for clinical use in the United States. Executive Chairman Dr Allan Syms discusses..
SYNC

Syncona appoints Norman Crighton to the Board

Syncona has appointed Norman Crighton as a non-executive director, with committee roles and shareholder priorities outlined...
GENF

Genflow Biosciences to present SLAB study data at Animal Longevity Summit 2026

Genflow Biosciences has been invited to present data from its SLAB study at the Animal Longevity Summit in Toronto in October 2026...
CIZ

Cizzle Biotechnology’s CIZ1B early lung cancer test gains CLIA accreditation in the US

Cizzle Biotechnology’s CIZ1B biomarker blood test has received CLIA accreditation at OmniHealth Diagnostics in Texas, enabling U.S. healthcare providers to order the early-stage lung cancer test...
AZN

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...
CIZ

Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test

Cizzle Biotechnology says the USPTO has allowed a patent application covering core methods used to measure its CIZ1B biomarker for early-stage lung cancer detection...
VRCI

Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

Verici Dx has completed its WRAP Retail Offer, raising approximately £0.19 million in additional gross proceeds and increasing total proceeds to about £2.6 million...
GSK

GSK receives orphan designations for momelotinib in VEXAS syndrome

GSK has received orphan drug designations for momelotinib in the US and EU for VEXAS syndrome, with phase II/III development planned...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets a clear need in lung cancer screening

Cizzle Bio is advancing its CIZ1B blood test as a complementary tool designed to support earlier lung cancer detection and risk assessment...
BIOG

Biotech Growth Trust reports strong one-year performance

Biotech Growth Trust PLC reported a 1-year NAV total return of 87.3% and share price total return of 82.7%, ahead of the benchmark’s 47.4%. Longer-term results were mixed, with 5-year..
EDX Medical Group plc

EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical is supporting a Scottish prostate cancer testing programme for 25,000 men, strengthening its position in early cancer detection and practical diagnostic services...
Genflow Biosciences Plc

Genflow Biosciences targets longevity market with gene therapy approach

Genflow Biosciences is positioning its SIRT6 gene therapy platform within the growing longevity biotech sector, where investors are increasingly focused on clinical evidence and clear development pathways...
BIOG

Biotech Growth Trust benefits as small-cap biotech bets pay off

Biotech Growth Trust delivered a strong year as its exposure to smaller biotech companies benefited from improved sentiment, a better interest-rate backdrop and rising takeover activity...
BIOG

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

Biotech Growth Trust notes GSK’s agreed $10.6bn cash acquisition of Nuvalent, a BIOG portfolio company focused on targeted cancer therapies...
VRCI

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising...
ETHY

Ethtry reaches 1,000 ETH following further Ethereum purchase

Ethtry PLC has purchased an additional 75 ETH for £93,750, bringing its fully staked Ethereum treasury to 1,000 ETH as part of its ongoing treasury strategy...
BIOG

Why biotech’s next phase is becoming more investable

Biotech investment interest is being supported by pharma patent pressures, renewed capital flows and breakthrough science creating new opportunities for scalable companies...
Ethtry plc

Ethtry offers investors listed exposure to Ethereum treasury growth

Ethtry is positioning itself as a listed route into Ethereum treasury exposure, with formal custody, governance and reporting controls...

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest Interviews

BrokerTalk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

GENF

Genflow Biosciences to Attend BIO San Diego as Chairman Gad Berdugo Joins mRNA Panel

Genflow Biosciences will attend BIO San Diego, with chairman Gad Berdugo joining an mRNA panel...
GSK

GSK gains US FDA approval for oral cUTI antibiotic Utebzi

GSK has secured US FDA approval for Utebzi, an oral carbapenem antibiotic for certain adult patients with complicated urinary tract infections...
Cizzle Biotechnology

Cizzle Biotechnology US Launch Opens the Door to Lung Cancer Test Royalties (video)

Cizzle Biotechnology has reached a pivotal commercial milestone, with its CIZ1B lung cancer blood test now available for clinical use in the United States. Executive Chairman Dr Allan Syms discusses the royalty opportunity.....
SYNC

Syncona appoints Norman Crighton to the Board

Syncona has appointed Norman Crighton as a non-executive director, with committee roles and shareholder priorities outlined...
GENF

Genflow Biosciences to present SLAB study data at Animal Longevity Summit 2026

Genflow Biosciences has been invited to present data from its SLAB study at the Animal Longevity Summit in Toronto in October 2026...
CIZ

Cizzle Biotechnology’s CIZ1B early lung cancer test gains CLIA accreditation in the US

Cizzle Biotechnology’s CIZ1B biomarker blood test has received CLIA accreditation at OmniHealth Diagnostics in Texas, enabling U.S. healthcare providers to order the early-stage lung cancer test...
AZN

Astrazeneca Plc gains US approval for Truqap in PTEN-deficient prostate cancer

Astrazeneca Plc has gained US approval for Truqap with abiraterone and prednisone in PTEN-deficient metastatic prostate cancer...
CIZ

Cizzle Biotechnology secures US patent allowance for CIZ1B lung cancer biomarker test

Cizzle Biotechnology says the USPTO has allowed a patent application covering core methods used to measure its CIZ1B biomarker for early-stage lung cancer detection...
VRCI

Verici Dx completes WRAP Retail Offer and raises additional gross proceeds

Verici Dx has completed its WRAP Retail Offer, raising approximately £0.19 million in additional gross proceeds and increasing total proceeds to about £2.6 million...
GSK

GSK receives orphan designations for momelotinib in VEXAS syndrome

GSK has received orphan drug designations for momelotinib in the US and EU for VEXAS syndrome, with phase II/III development planned...
Cizzle Biotechnology Holdings plc

Cizzle Bio targets a clear need in lung cancer screening

Cizzle Bio is advancing its CIZ1B blood test as a complementary tool designed to support earlier lung cancer detection and risk assessment...
BIOG

Biotech Growth Trust reports strong one-year performance

Biotech Growth Trust PLC reported a 1-year NAV total return of 87.3% and share price total return of 82.7%, ahead of the benchmark’s 47.4%. Longer-term results were mixed, with 5-year NAV growth of 9.4% versus 33.6% for the benchmark...
EDX Medical Group plc

EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical is supporting a Scottish prostate cancer testing programme for 25,000 men, strengthening its position in early cancer detection and practical diagnostic services...
Genflow Biosciences Plc

Genflow Biosciences targets longevity market with gene therapy approach

Genflow Biosciences is positioning its SIRT6 gene therapy platform within the growing longevity biotech sector, where investors are increasingly focused on clinical evidence and clear development pathways...
BIOG

Biotech Growth Trust benefits as small-cap biotech bets pay off

Biotech Growth Trust delivered a strong year as its exposure to smaller biotech companies benefited from improved sentiment, a better interest-rate backdrop and rising takeover activity...
BIOG

GSK to acquire Biotech Growth Trust portfolio company Nuvalent for $10.6bn

Biotech Growth Trust notes GSK’s agreed $10.6bn cash acquisition of Nuvalent, a BIOG portfolio company focused on targeted cancer therapies...
VRCI

Verici Dx publishes Circular and Notice of General Meeting

Verici Dx has published a circular convening a general meeting on 22 June 2026 to seek authority to issue new ordinary shares on a non-pre-emptive basis following its recent fundraising...
ETHY

Ethtry reaches 1,000 ETH following further Ethereum purchase

Ethtry PLC has purchased an additional 75 ETH for £93,750, bringing its fully staked Ethereum treasury to 1,000 ETH as part of its ongoing treasury strategy...
BIOG

Why biotech’s next phase is becoming more investable

Biotech investment interest is being supported by pharma patent pressures, renewed capital flows and breakthrough science creating new opportunities for scalable companies...
Ethtry plc

Ethtry offers investors listed exposure to Ethereum treasury growth

Ethtry is positioning itself as a listed route into Ethereum treasury exposure, with formal custody, governance and reporting controls...
Load More

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

Green News

View all Sustainable sectors, Plcs and news >>  

Search

Search

Latest interviews

Broker Talk

Funds

View all Funds, Market Insights and news >> 

FTSE 100 News

UK Broker Ratings

Health

Latest Interviews

FTSE 100 News

FTSE 250 News

News and Interview Alerts

Subscribe Free

Company Presentations

Q&As

Hardman & Co

BrokerTalk

FTSE 100

Funds

View all Funds, Market Insights and news >> 

Green News

View all Sustainable sectors, Plcs and news >>  

UK Broker Ratings

Follow us on Social Media:

Home X-twitter Linkedin Facebook Spotify Apple